SB 204741 manufacturers
- SB 204741
-
- $48.00
-
2026-07-15
- CAS:152239-46-8
- Purity: 99.86%
- Supply Ability: 10g
- SB 204741
-
- $1.00
-
2024-10-22
- CAS:152239-46-8
- Min. Order: 1KG
- Purity: MIn98%HPLC/LC
- Supply Ability: 100KGS
|
| | SB 204741 Basic information |
| Product Name: | SB 204741 | | Synonyms: | SB 204741;N-(1-METHYL-1H-5-INDOLYL)-N'-(3-METHYL-5-ISOTHIAZOLYL)UREA;N-(1-METHYL-1H-INDOLYL-5-YL)-N''-(3-METHYL-5-ISOTHIAZOLYL)UREA;1-(1-Methyl-1H-indol-5-yl)-3-(3-Methylisothiazol-5-yl)urea;3-(3-METHYL-1,2-THIAZOL-5-YL)-1-(1-METHYLINDOL-5-YL)UREA;1-(1-methyl-5-indolyl)-3-(3-methyl-5-isothiazolyl)urea;Urea, N-(1-methyl-1H-indol-5-yl)-N'-(3-methyl-5-isothiazolyl)-;human,inhibit,SB204741,5-HT Receptor,Inhibitor,remodeling,Serotonin Receptor,selective,SB 204741,isoproterenol-induced,affinity,SB-204741,5-hydroxytryptamine Receptor,myocardial | | CAS: | 152239-46-8 | | MF: | C14H14N4OS | | MW: | 286.35 | | EINECS: | | | Product Categories: | API | | Mol File: | 152239-46-8.mol |  |
| | SB 204741 Chemical Properties |
| Melting point | >195°C (dec.) | | storage temp. | 2-8°C | | solubility | DMSO: ~18 mg/mL, soluble | | form | solid | | color | orange | | Stability: | Hygroscopic | | InChI | InChI=1S/C14H14N4OS/c1-9-7-13(20-17-9)16-14(19)15-11-3-4-12-10(8-11)5-6-18(12)2/h3-8H,1-2H3,(H2,15,16,19) | | InChIKey | USFUFHFQWXDVMH-UHFFFAOYSA-N | | SMILES | N(C1C=CC2=C(C=1)C=CN2C)C(NC1SN=C(C)C=1)=O |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | SB 204741 Usage And Synthesis |
| Uses | SB 204741 is a potent, selective SR-2B antagonist. | | Definition | ChEBI: 1-(1-methylindol-5-yl)-3-(3-methyl-1,2-thiazol-5-yl)urea is a member of ther class of ureas that is urea in which a hydrogen attached to one of the nitrogens has been replaced by an N-methylindol-5-yl group, while a hydrogen attached to the other nitrogen has been replaced by a 3-methyl-1,2-thiazol-5-yl group. It is a potent and selective antagonist for the 5-hydroxytryptamine 2B (5-HT2B) receptor. It has a role as a receptor modulator and a serotonergic antagonist. It is a member of ureas, a member of indoles and a member of 1,2-thiazoles. | | Biological Activity | Potent and selective 5-HT 2B receptor antagonist (pA 2 = 7.95). Displays ≥ 135-fold selectivity over 5-HT 2C (pK i = 5.82), 5-HT 2A (pK i < 5.2), 5-HT 1A , 1D , 1E , 5-HT 3 and 5-HT 4 receptors. | | in vivo | SB-204741 (0.25~1.0 mg/kg; i.p.) induces myocardial remodeling and dose dependently improves hemodynamic and ventricular functions following isoproterenol-induced myocardial injury[1].
SB-204741 bolsters endogenous anti-oxidant enzymes activities, improves cardiac injury markers, NO level and lipid peroxidation level and attenuates TNFα level in isoproterenol-induced myocardial remodeling in rats. SB-204741 (0.5 and 1.0 mg/kg/day) pre-treatment for 28 days significantly amplifies NO level and GSH and SOD activities and attenuates TBARS level following isoproterenol-induced myocardial remodeling. SB-204741 inhibits inflammatory protein expression, upregulates autophagy and HSPs protein expressions in isoproterenol-induced myocardial remodeling in rats. SB-204741 improves myocardial architecture in isoproterenol-induced myocardial remodeling in rats[1]. | Animal Model: | Rats[1] | | Dosage: | 0.25~1.0 mg/kg | | Administration: | I.p. | | Result: | Induced myocardial remodeling.
|
| | IC 50 | human 5-HT2B Receptor: 7.1 (pKi) | | storage | Room temperature |
| | SB 204741 Preparation Products And Raw materials |
|